Edition:
United States

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

28.41USD
17 Nov 2017
Change (% chg)

$0.72 (+2.60%)
Prev Close
$27.69
Open
$28.00
Day's High
$28.68
Day's Low
$27.37
Volume
237,311
Avg. Vol
243,130
52-wk High
$29.21
52-wk Low
$13.51

Latest Key Developments (Source: Significant Developments)

Adamas Pharmaceuticals reports Q3 loss per share $1.04
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results.Q3 loss per share $1.04.Q3 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Adamas Pharmaceuticals Inc - ‍ expects to receive $65 million in funding from healthcare royalty partners in q4 of 2017.Adamas Pharmaceuticals Inc - ‍ believe we will be sufficiently capitalized to launch and commercialize gocovri, among others​.  Full Article

Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals
Wednesday, 1 Nov 2017 09:01am EDT 

Nov 1 (Reuters) - Adamas Pharmaceuticals Inc :Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​.  Full Article

Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​
Friday, 27 Oct 2017 04:29pm EDT 

Oct 27 (Reuters) - Adamas Pharmaceuticals Inc :Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​.  Full Article

Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI
Wednesday, 25 Oct 2017 12:30pm EDT 

Oct 25 (Reuters) - Adamas Pharmaceuticals Inc ::FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI.  Full Article

Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals‍​
Thursday, 7 Sep 2017 04:47pm EDT 

Sept 8 (Reuters) - Adamas Pharmaceuticals Inc :Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing .‍​.  Full Article

Adamas announces FDA approval of Gocovri as first and only medication for dyskinesia treatment in Parkinson’s disease patients
Thursday, 24 Aug 2017 04:16pm EDT 

Aug 24 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals Inc - ‍Gocovri is expected to be available in Q4, and formally launched in Jan 2018​.  Full Article

Adamas Pharmaceuticals Q2 loss per share $0.93
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Adamas Pharmaceuticals Inc :Adamas reports recent achievements and second quarter 2017 financial results.Q2 loss per share $0.93.Q2 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S.  Full Article

Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology
Monday, 12 Jun 2017 04:01pm EDT 

June 12 (Reuters) - Adamas Pharmaceuticals Inc :Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology.Adamas Pharmaceuticals Inc - new drug application for ADS-5102 currently under FDA review with August 24, 2017 PDUFA date.  Full Article

Adamas presents positive phase 1A data
Monday, 22 May 2017 08:30am EDT 

May 22 (Reuters) - Adamas Pharmaceuticals Inc ::Adamas presents positive phase 1A data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.Adamas Pharmaceuticals - phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of vimpat.Says multi-dose phase 1b steady state study ongoing, with topline data expected in Q3 2017.Adamas Pharmaceuticals - data from study showed all four formulations of ADS-4101 to be safe and well tolerated when compared to vimpat-treated group.  Full Article

Adamas Pharmaceuticals enters into sales agreement with Cowen
Thursday, 11 May 2017 09:10am EDT 

May 11 (Reuters) - Adamas Pharmaceuticals Inc :Entered into sales agreement with Cowen and co, relating to potential common stock offering of up to $50 million of its shares.  Full Article

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results